Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer medicine"
DOI: 10.1101/2022.07.21.22277915
Abstract: Background: There is much uncertainty regarding the comparative risks of cancer for T2DM patients on SGLT2I versus DPP4I. Methods: This population-based cohort study patients included T2DM patients who were administered with either SGLT2I or DPP4I… read more here.
Keywords: new onset; overall cancer; population based; onset overall ... See more keywords